Bristol Myers Squibb has implemented Veeva Systems’ trial management and monitoring software for clinical study processes across the globe.
The implementation of Veeva Vault CTMS was carried out in less than 20 months.
Veeva’s monitoring software, which is integrated with the company’s eTMF and Study Startup applications, replaced a heritage Celgene CTMS and a Bristol Myers Squibb CTMS.
Bristol Myers Squibb chief digital and technology officer Greg Meyers said: “We’re thrilled to expand on our longstanding partnership with Veeva across R&D.
“Veeva’s continued commitment to customer success and product innovation helps us accelerate the development and delivery of medicines to patients globally.”
Vault CTMS provides a real-time view of trial status across processes and enhances efficiency in operations.
Furthermore, the software streamlines partnerships, and enables quality clinical trial execution. It provides one system of record for shared study start-up.
Based on categories such as visit frequency, protocol, and procedures, Vault CTMS enables seamless planning of participant visits.
Additionally, study teams will obtain a complete view of interactions between sponsors, contract research organisations, investigators, and personnel at the site.
Bristol Myers Squibb established simple clinical trial processes to make studies faster, with the implementation of Veeva’s software across the company.
Veeva CEO Peter Gassner said: “The merger of Bristol Myers Squibb and Celgene was the largest IT integration project in the history of pharma and to have completed a single CTMS implementation in twenty months is truly remarkable.”
In October last year, Veeva Systems launched the Veeva Digital Trials Platform for streamlined clinical trial execution.